Arch Biopartners (FRA:8HA) Pretax Margin %: % (As of Mar. 2026)

What is Arch Biopartners Pretax Margin %?

Arch Biopartners FRA:8HA -15.27% 8 Pretax Margin % is % as of Mar. 2026. GuruFocus rates FRA:8HA with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, Arch Biopartners ranks worse than 105708.14% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Arch Biopartners's Pre-Tax Income for the three months ended in Mar. 2026 was €-0.33 Mil. Arch Biopartners's Revenue for the three months ended in Mar. 2026 was €0.00 Mil. Therefore, Arch Biopartners's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Arch Biopartners's Pretax Margin % or its related term are showing as below:

FRA:8HA's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -90.5
* Ranked among companies with meaningful Pretax Margin % only.

Arch Biopartners (FRA:8HA) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Arch Biopartners Pretax Margin % Related Terms

Arch Biopartners Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Arch Biopartners's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Biopartners Pretax Margin % Chart

Arch Biopartners Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

Pretax Margin %

Get a 7-Day Free Trial

0.00

Arch Biopartners Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Pretax Margin %	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

FRA:8HA vs VRTX, REGN, ALNY: Pretax Margin % Comparison

For the Biotechnology subindustry, Arch Biopartners's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arch Biopartners Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Pretax Margin % falls into.

Save Embed

8GF Score

Arch Biopartners Inc FRA:8HA

Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Arch Biopartners Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Arch Biopartners's Pretax Margin for the fiscal year that ended in Sep. 2025 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Sep. 2025 )	/	Revenue (A: Sep. 2025 )
	=	-0.956	/	0
	=	%

Arch Biopartners's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-0.328	/	0
	=	%

Frequently Asked Questions Learn more about Pretax Margin % →

What does a Pretax Margin % of % mean?

Arch Biopartners (FRA:8HA) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Arch Biopartners and its competitors. According to the industry distribution chart, Arch Biopartners ranks #999999 out of 946 companies in the Biotechnology industry.

Is Arch Biopartners' Pretax Margin % too high?

Arch Biopartners' current Pretax Margin % is %. Based on the distribution chart, Arch Biopartners ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arch Biopartners has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.

How does Arch Biopartners' Pretax Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Arch Biopartners ranks #999999 out of 946 companies for Pretax Margin %. This places Arch Biopartners in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Pretax Margin % for a Biotechnology company?

A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Pretax Margin % mean?

A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Arch Biopartners and its competitors. Arch Biopartners's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Arch Biopartners stock overvalued right now?

Arch Biopartners (FRA:8HA) has a current Pretax Margin % of %. The current Pretax Margin % is %. Arch Biopartners' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Pretax Margin % calculated?

Pretax Margin % is calculated from a company's financial statements. For Arch Biopartners (FRA:8HA), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Biopartners Business Description

Industry Healthcare Biotechnology

Comparable Companies TSX:RVX XCNQ:LOBE TSXV:GSD TSXV:TTI TSX:MDNA TSX:BCT TSX:MBX XCNQ:MDMA TSXV:MIR NEOE:BMND VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges ACHFF:USA ARCH:Canada

Address 545 King Street West, Toronto, ON, CAN, M5V 1M1

Website https://www.archbiopartners.com

Arch Biopartners Inc is a developer of a therapeutic pipeline designed to address acute kidney injury (AKI) and chronic kidney disease (CKD) by targeting inflammation- and toxin-related kidney damage. The group offers mechanism-based treatments, enabling patients suffering from both acute and chronic kidney conditions to benefit from novel, targeted therapies that address unmet medical needs in kidney care.

8GF Score

Get the complete analysis for FRA:8HA

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.50

Price

View FRA:8HA Analysis

See Pretax Margin % data for all stocks →